Avalo Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Avalo Therapeutics generated cash of -$30,680,000, which is less than the previous year. Cash used in financing activities reached the amount of $25,042,000 last year. Net change in cash is therefore -$5,771,000.
Cash Flow
| 2014 | -15.51M | -19.50K | 23.85M |
|---|---|---|---|
| 2015 | -10.16M | -19.98K | 19.60M |
| 2016 | -14.57M | -34.88K | -1.42M |
| 2017 | 12.51M | -18.91M | 3.73M |
| 2018 | -3.12M | 865.46K | 10.40M |
| 2019 | -19.13M | -443.00K | 12.55M |
| 2020 | -40.53M | 11.13M | 44.78M |
| 2021 | -70.89M | -113K | 106.76M |
| 2022 | -26.75M | -95K | -14.69M |
| 2023 | -30.68M | -133K | 25.04M |
AVTX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 13.31M | 54.86M | 19.10M | 3.72M | 10.74M | 2.60M | 5.12M | 21.16M | 11.74M | 3.42M |
Operating activities | ||||||||||
Net income | -31.54M | -41.65M | -84.37M | -63.49M | -16.07M | -40.05M | 11.86M | -16.47M | -10.49M | -16.05M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 158K | 166K | 1.65M | 1.84M | 3.88M | 4.55M | 425.47K | 26.85K | 23.50K | 28.94K |
Stock-based compensation expense | 3.47M | 7.55M | 8.17M | 6.78M | 2.53M | 0 | 1.15M | 1.69M | 394.74K | 1.08M |
| Deferred income tax benefit | 3.47M | 7.55M | 8.17M | 6.78M | 2.53M | 0 | 1.15M | 1.69M | 394.74K | 1.08M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 1.78M | 1.06M | 1.11M | -678.10K | 1.65M | -222.53K | -247.19K | -132.47K | 0 | 0 |
Inventories | 20K | 18K | -35K | 18.19K | 532.94K | -311.19K | -202.62K | 0 | 0 | 0 |
Accounts payable | -2.43M | -487K | 796K | 98.52K | 1.01M | 82.45K | 96.06K | 332.1K | -268.70K | -708.36K |
Cash generated by operating activities | -30.68M | -26.75M | -70.89M | -40.53M | -19.13M | -3.12M | 12.51M | -14.57M | -10.16M | -15.51M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | -11.19T | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -158K | -95K | -113K | -62.65K | -262.01K | -564.41K | -23.32K | -34.88K | -19.98K | -19.50K |
Acquisitions Net | 0 | 0 | 0 | 11.19M | 3.95M | 1.42M | -18.88M | 0 | 0 | 0 |
Cash generated by investing activities | -133K | -95K | -113K | 11.13M | -443.00K | 865.46K | -18.91M | -34.88K | -19.98K | -19.50K |
Financing activities | ||||||||||
Common Stock Issued | 46.21M | 0 | 73.86M | 44.45M | 12.68M | 3.85M | 6.34M | 2.00M | 23.68M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -14.80M | 0 | -93.86K | -33.95K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -21.24M | 0 | -32.9M | 0 | -256.13K | 0 | -2.37M | -3.31M | -1.81M | -7.39M |
Cash used in financing activities | 25.04M | -14.69M | 106.76M | 44.78M | 12.55M | 10.40M | 3.73M | -1.42M | 19.60M | 23.85M |
Net Change In Cash | -5.77M | -41.54M | 35.75M | 15.37M | -7.01M | 8.14M | -2.65M | -16.03M | 9.41M | 8.32M |
Cash at end of period | 7.54M | 13.31M | 54.86M | 19.10M | 3.72M | 10.74M | 2.47M | 5.12M | 21.16M | 11.74M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |